en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu

MSA News

“Sticking With MSA” -Dr. Wouter Peelearts (Researcher, Michigan)

“Sticking With MSA” -Dr. Wouter Peelearts (Researcher, Michigan)

Sticking with Multiple System Atrophy

Multiple System Atrophy (MSA) is a rare brain disorder that until recently was largely ignored by the research community. MSA is a rapidly progressing neurodegenerative disease caused by a decline of the body’s most basic and vital functions including breathing, digestion, urination, controlling blood pressure and movement.

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MODAG Collaboration Update – MSA Drug

MODAG Collaboration Update – MSA Drug

Congratulations to MODAG! On behalf of MSA/AMS patients around the world, we are thankful for your efforts! 💜. https://www.tevapharm.com/news-and-media/latest-news/teva-and-modag-announce-licensing-collaboration-for-neurodegenerative-disease-drug-candidate/

*NEW * RESEARCH UPDATE FROM BIOHAVEN RE: VERDIPERSTAT (BHV-3241)

*NEW * RESEARCH UPDATE FROM BIOHAVEN RE: VERDIPERSTAT (BHV-3241)

Timeline: International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy "Top line results from the study are expected to be available in 3Q2021 and will help to characterize the potential benefits and risks of Verdiperstat in MSA. After the study...

REGISTER NOW – MSA VIRTUAL FREE CONFERENCE, SEPT 24-OCT 2

REGISTER NOW – MSA VIRTUAL FREE CONFERENCE, SEPT 24-OCT 2

Defeat MSA Canada/Vaincre AMS Canada, Defeat MSA Alliance (US) and allied charities in the MSA United Consortium are pleased to announce the Second All-Community MSA Virtual Conference, Sept 24-Oct 2, 2021. This year's conference will include several exciting...

LOOKING FOR OTHER WAYS TO GET INVOLVED?

JOIN THE MOVEMENT TO #DEFEATMSA

 

Follow us on social media

Follow us on Twitter

Follow us on Facebook

Follow us on Instagram

Follow us on YouTube

 

Follow us on social media

Follow us on Twitter

Follow us on Facebook

Follow us on Instagram

Follow us on YouTube

Follow us on LinkedIn

Copyright 2021 | Defeat MSA CaNADA -  a REGISTERED CHARITABLE Organization | PRIVACY POLICY

CREATEDBYRIOSMEDIA

English
Copy link
Powered by Social Snap